Authors


Robert Dreicer, MD

Latest:

Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer

Robert Dreicer, MD, describes the future of metastatic castration-resistant prostate cancer.


Alexander Kutikov, MD, FACS

Latest:

Current Unmet Needs in ccRCC Diagnosis

Imaging advancements in ccRCC are crucial for predicting tumor biology and enhancing treatment strategies through molecular imaging techniques.


Seth Bechis, MD

Latest:

Future Perspectives in the Treatment of Patients With Urinary Stones

Drs Bechis and Semins discuss future developments in urinary stone management, emphasizing the potential for improved vacuum aspiration devices, combined intravenous and PCNL surgeries, and the hope for medications to dissolve stones.


Jindan Yu, MD, PhD

Latest:

Jindan Yu, MD, highlights ongoing prostate cancer research projects

"We are trying to develop epigenetic biomarkers that can predict patients that are starting to progress to neuroendocrine prostate cancer," says Jindan Yu, MD, PhD.


Gia Ching

Latest:

The benefits of working with a consultant when starting a private urology practice

"Just having someone with another set of eyes I think is always helpful and gives you a lot of inspiration as well as a lot of encouragement on exactly what you need to do next," says Gia Ching.


Sponsored Content by Ferring Pharmaceuticals

Latest:

Demystifying Vector-Based Intravesical Gene Therapy for NMIBC: A New Frontier

Neal Shore, MD, FACS, is a U.S. Chief Medical Officer at GenesisCare USA and Medical Director of the Carolina Urologic Research Center. He also was an investigator on the Phase 2 and 3 studies in the clinical trial program for nadofaragene firadenovec-vncg.


Óscar Rodríguez-Faba, MD, PhD, FEBU

Latest:

Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBC

Panelists discuss the characteristics of an ideal multidisciplinary team for managing BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC), emphasizing the need for oncologists and urologists to collaboratively prepare for successful patient outcomes across different markets, while also identifying necessary educational resources and highlighting adverse events that require attention in preparation for product launches.


Pooja Ghatalia, MD

Latest:

Pooja Ghatalia, MD, on interim findings from RETAIN-2 trial in MIBC

"We see that among the patients who went on to receiving cystectomy, 84% are metastases free," says Pooja Ghatalia, MD.


Jiping Zeng, MD

Latest:

The role of surgery continues to evolve in seminoma

"RPLND is an attractive option for those who prefer to avoid chemotherapy," write Jiping Zeng, MD; Timothy A. Masterson, MD; and Clint Cary, MD, MPH, MBA.


Antony Mathew, MD

Latest:

PARP inhibitors: Treating mCRPC from a genetic basis

Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.


Tracy M. Downs, MD, FACS

Latest:

Diversity in Urology: Progress made, but there is more work to be done

Kelvin Moses, MD, PhD, interviews Tracy M. Downs, MD, about progress and remaining challenges regarding diversity, equity, and inclusion in the field of urology.


Adam B. Weiner, MD

Latest:

De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment options

A prostate cancer expert breaks down likelihood of a diagnosis of metastatic prostate cancer and touches on available treatment options.


Sarah P. Psutka, MD, MSc

Latest:

Sarah Psutka, MD, on phase 3 trial of padeliporfin VTP therapy in UTUC

“This is another therapeutic that adds to UroGen [profile] as a potential treatment that could be used to preserve kidneys while treating low grade upper tract urothelial carcinoma going forward,” says Sarah P. Psutka, MD, MSc.


Krinio Giannikou, PhD, MSc

Latest:

The evolving role of microRNAs in testicular cancer management

"This brief review captures the evolving role of miRNAs, focusing on their clinical relevance and implications as well as future directions for more effective targeted therapeutic interventions," write the authors.


Kara Cossis, PA-C, MPH

Latest:

Kara Cossis, PA-C, MPH, on the role of APPs in genetic testing

APPs can help in introducing genetic testing and in the interpretation of results, according to Kara Cossis, PA-C, MPH.


Melissa A. Laudano, MD

Latest:

Experts discuss expanding use of vibegron for OAB

Grace Khaner and Melissa A. Laudano, MD, share their thoughts on the potential for expanding the use of vibegron early in treatment for OAB.


Jeff Bendix

Latest:

What steps can physicians take to overcome barriers to health equity?

“Things we have control over are ourselves, our care team, and to some extent, our care model,” said Sarah Candler, MD.


Jitesh Dhingra, MD, FRCEM

Latest:

Expert shares anticipated research directions for PSMA-PET in prostate cancer

"I would basically look at these 3 things as the major things to be coming up," says Jitesh Dhingra, MD, FRCEM.


Ashling Wahner

Latest:

177Lu-PSMA-617 prolongs rPFS in taxane-naïve mCRPC, benefit greater with prior abiraterone vs enzalutamide

Lutetium Lu 177 vipivotide tetraxetan improved rPFS vs switching to abiraterone acetate or enzalutamide in patients with taxane-naïve mCRPC who had progressed on prior abiraterone or enzalutamide. Outcomes were better, however, in patients who initially received abiraterone.


Brendan T. Frainey, MD

Latest:

Brendan Frainey, MD, on microbiome composition in patients with spina bifida

"The notion that the urine is sterile should be hopefully abolished by now, especially in this group where we know that these individuals do have a lot of bacteria growing in their bladders," says Brendan T. Frainey, MD.


Kara L. Watts, MD

Latest:

Kara Watts, MD, outlines SUO 2024 session on salvage focal ablation

"I think the highlights are the functional outcomes after a salvage focal ablation are favorable, definitely, compared to salvage radical prostatectomy, but the studies are quite limited in terms of real salvage focal ablation," says Kara L. Watts, MD.


Timothy A. Masterson, MD

Latest:

The role of surgery continues to evolve in seminoma

"RPLND is an attractive option for those who prefer to avoid chemotherapy," write Jiping Zeng, MD; Timothy A. Masterson, MD; and Clint Cary, MD, MPH, MBA.


Brian M. Shuch, MD

Latest:

Potential Impact of PET/CT Imaging on Improving Patient Care

Neal Shore, MD, FACS, and Brian Shuch, MD, provide closing thoughts on the potential of PET/CT imaging to improve patient care in kidney cancer.


John J. Kowalczyk, DO, FACOS

Latest:

Current Shortcomings in the Modern Urology Practice Management Landscape

A urologist practicing in California defines the remaining general and region-specific challenges he faces in managing his practice and his hopes for future solutions.


Bogdana Schmidt, MD, MPH

Latest:

Case 1: A 79-Year-Old Man With Non–Muscle-Invasive Bladder Cancer

Panelists discuss how they approach a typical bladder cancer case of a 79-year-old man with hematuria, including initial diagnostic procedures, the importance of proper tumor measurement during resection, BCG therapy protocols, and management options for BCG-unresponsive disease with a focus on nadofaragene firadenovec (Adstiladrin).


Mark D. Tyson, II, MD, MPH

Latest:

An Overview Of Pembrolizumab for High-Risk BCG Unresponsive NMIBC

Panelists discuss how pembrolizumab, a PD-1 inhibitor, offers a systemic immunotherapy option for high-risk, BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) by enhancing the immune system’s ability to target cancer cells, with intravenous administration and careful monitoring for immune-related adverse effects.


Joeseph Renzulli, MD

Latest:

Managing Cognitive and Sexual Health in Prostate Cancer Patients on Hormonal Therapy

Panelists discuss how managing cognitive and sexual health in prostate cancer patients undergoing hormonal therapy is crucial, emphasizing the need for proactive communication and tailored interventions to enhance overall quality of life.


Phillip Koo, MD

Latest:

Closing Thoughts on the Impact of PSMA-PET Imaging in Prostate Cancer

Experts summarize how the use of PSMA-PET imaging has impacted the field to date and share their hopes for the future.


Timothy D. Lyon, MD

Latest:

Timothy Lyon, MD, on recent change to outpatient complications metric in urology rankings

"We have communicated with Solventum, who makes this software, and they have made changes based on our feedback," says Timothy D. Lyon, MD.


Naveen Kella, MD, The Urology Place

Latest:

Continued Advances and Unmet Needs in PSMA-Based Imaging for Prostate Cancer

Experts Naveen Kella, MD, and Dr. Shadi Esfahani, MD, MPH, consider the continued impact of PSMA PET imaging on prostate cancer management and emerging modalities that could revolutionize patient care.

© 2025 MJH Life Sciences

All rights reserved.